Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$63.65−0.23 (-0.36%)
Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –
Eton Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Eton Pharmaceuticals's price to sales ratio was 18.3× on Nov 11, 2026, against 6.2× a year earlier. Over the last 5 years it ranged from 2.5× to 18.3×, with a median of 5.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 18.3× | +11.9 |
| 2025 | Dec 31, 2025 | 6.4× | −3.5 |
| 2024 | Dec 31, 2024 | 9.9× | +6.5 |
| 2023 | Dec 29, 2023 | 3.4× | −0.4 |
| 2022 | Dec 30, 2022 | 3.8× | −2.9 |
| 2021 | Dec 31, 2021 | 6.7× | −402.5 |
| 2020 | Dec 31, 2020 | 409.2× | – |
See a number that looks wrong?